French lawmakers are setting the scene for a showdown with manufacturers defending their drug prices with R&D investment figures.
Rising drug prices in the US are hot topic. Inbeeo takes a look at the recent drug pricing proposal by the Democrats suggesting the use of ERP.
Was the reaction to the $2.15m Zolgensma list price a tropical cyclone or more of a storm in a teacup?
Inbeeo’s analysis of 2018 drug pricing tweets using NLP machine learning techniques highlight how emotive the issue of pharmaceutical pricing really is.
What is Value-Based Pricing? It’s pricing based on value! Or is it? Let us try to define what it is once and for all.
France’s healthcare industry strategic council CSIS met an agreement with the French Government to strengthen France’s appeal for HealthCare industries. Inbeeo dives in to investigate the impact on market access and pricing.
No one will argue that Medicare Part D met a genuine need at its inception in the mid-2000s – offering Medicare beneficiaries an affordable voluntary health insurance plan that would cover their outpatient prescription needs. Fast forward 10 years. Has Part D met its objective? In terms of the availability of a wide range of plans at an affordable premium in all parts of the nation, yes, definitely. In terms of actual payments made to beneficiaries, this is a question mark.
The event that made people pay attention to how prescription drugs are being priced
The value-denial syndrome used to be broadly shared between payers and the industry, and now they both seem to come to the same realization that value-based pricing is the only way. Easier said than done, but that’s a start.
Whatever happens next in the US and elsewhere, life science companies must take charge and own the value story behind their innovative products. It starts by understanding and mastering value assessment frameworks. An Inbeeo thought experiment.
